Hematologic Diseases

Cytogenetic abnormalities commonly associated with acute myeloid leukemia (AML) are detected by fluorescence in situ hybridization (FISH). Probes for MECOM (3q26.2), DEK/NUP214 t(6;9), RUNX1T1/RUNX1 t(8;21), KMT2A (MLL)(11q23.3), PML/RARA t(15;17) and CBFb/MYH11 inv(16) are included in the AML FISH Profile.

disease state indication(s)
Acute myeloid leukemia (AML)

clinical use
The AML FISH Profile detects cytogenetic abnormalities that are included in the World Health Organization (WHO) classification of acute myeloid leukemia (AML) with recurrent genetic abnormalities.

methodology/product platform
Fluorescence in situ hybridization (FISH)

specimen type and requirements
Peripheral blood: 5-6 mL in sodium heparin (green-top) tube.
Bone marrow: 2-3 mL in sodium heparin (green-top) tube.
Bodily fluids: Bodily fluids for diagnostic testing of hematological cancers (subject to specimen viability). Preferred transport in equal parts RPMI.
Lymphoid tissue: Transport in RPMI. FFPE tissue: no decalcification.
Note: Use refrigerated cold pack for transport. Make sure cold pack is not in direct contact with specimen.
DO NOT FREEZE.

Probe Prioritization: If samples are insufficient to complete the whole FISH panel, Genoptix will contact client to prioritize testing,

turnaround time
Tech-only (TC): 3 days
Global (TC & PC): 5 days

cpt code(s)
88377 (x6)

medicare moldx cpt code
Not applicable

regulatory classification
Laboratory developed test (LDT)

ordering option
Global (TC & PC) or Tech-only (TC)